Patents by Inventor Elizabeth E. Evans

Elizabeth E. Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding antibodies that bind to the C35 polypeptide
    Patent number: 7563882
    Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: July 21, 2009
    Assignee: University of Rochester
    Inventors: Maurice Zauderer, Elizabeth E. Evans
  • Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor Cells
    Publication number: 20090081210
    Abstract: The invention provides in vitro and in vivo methods of killing cancer cells, including therapeutic methods in humans, and also provides antibodies specific for the cancer specific antigen C35, and polynucleotides encoding such antibodies, as well as therapeutic and diagnostic methods of using such antibodies.
    Type: Application
    Filed: May 22, 2008
    Publication date: March 26, 2009
    Inventors: Elizabeth E. Evans, Mark J. Paris, Deepak M. Sahasrabudhe, Maurice Zauderer, Ernest S. Smith
  • Anti-C35 antibodies for treating cancer
    Publication number: 20080305111
    Abstract: The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and a chemotherapeutic agent. In some preferred embodiments, two C35 antibodies are administered with a chemotherapeutic agent. The present invention is further directed to C35 antibodies useful in these methods.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 11, 2008
    Applicant: VACCINEX, INC.
    Inventors: Elizabeth E. Evans, Mark J. Paris, Deepak M. Sahasrabudhe, Maurice Zauderer, Ernest S. Smith
  • Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
    Patent number: 7268207
    Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptides, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: September 11, 2007
    Assignee: University of Rochester
    Inventors: Maurice Zauderer, Elizabeth E. Evans, Melinda A. Borrello
  • Gene differentially expressed in breast and bladder cancer and encoded polypeptides
    Publication number: 20040063907
    Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.
    Type: Application
    Filed: June 10, 2003
    Publication date: April 1, 2004
    Inventors: Maurice Zauderer, Elizabeth E. Evans, Melinda A. Borrello
  • Gene differentially expressed in breast cancer, and encoded polypeptides
    Publication number: 20020155447
    Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptides, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.
    Type: Application
    Filed: April 4, 2001
    Publication date: October 24, 2002
    Inventors: Maurice Zauderer, Elizabeth E. Evans, Melinda A. Borrello